who should not take glp-1 medications Guidance from the MHRA, published in June 2025, on weightloss medication GLP-1s and Eye Health: What

doi: 10.4103/MJBL.MJBL_10_17 113 CivitarealeDSaiardiAFalascaP

At MNT , we dedicated a podcast episode to this

Meanwhile, obesity or overweight, worse renal function, unfavorable lipid profile (such as higher low-density lipoprotein cholesterol and lower high-density lipoprotein cholesterol), hypertension, and smoking are also associated with a higher risk of DPN ( 2.3 Pharmacological treatments for DPN According to the relevant guidelines in China released in 2021 ( 3 Preclinical evidence of neuroprotective effects of GLP-1R agonists in DPN In patients with DM, the metabolism of glucose, lipids, proteins, and nuclear acids is largely dysregulated

However, according to Aldhalei and colleagues, about a third of GLP-1 users experience constipation

The intake of Acetyl-Carnitine improves the athletes energy status in both power and endurance efforts